WALTHAM, Massachusetts, October 22 /PRNewswire/ --

- Significant Unmet Need Remains for Agents that are Effective in Treating Triple-Negative Breast Cancer, According to a New Report from Decision Resources

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that significant market penetration will drive Genentech/Roche/Chugai's Avastin to garner just over 20 percent of total sales in the breast cancer drug market in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan in 2017.

The new Pharmacor report entitled Breast Cancer finds that, through 2017, the breast cancer drug market will be driven by sales of Avastin in the U.S. and Europe, its approval and launch in Japan, and its label extension to the adjuvant setting in 2013.

Additionally, interviewed experts said they are strongly encouraged by the clinical trial data to date of Pfizer's Sutent and express confidence in the drug's potential in breast cancer, particularly for its potential in the treatment of triple-negative breast cancer. Triple-negative breast tumors -- which account for approximately one-fifth of all breast cancers -- are defined by their lack of expression of estrogen, progesterone and HER2 receptors.

Lack of receptor expression results in resistance to conventional hormonal and targeted therapies, leaving chemotherapy as the only treatment option for patients with triple-negative breast cancer, said Niamh Murphy, Ph.D., analyst at Decision Resources. As a result, there is a significant unmet need for the development of effective agents for the treatment of triple-negative breast cancer.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact: Decision Resources Decision Resources, Inc. Christopher Comfort Elizabeth Marshall +1-781-296-2597 +1-781-296-2563 ccomfort@dresources.com emarshall@dresources.com Web site: http://www.decisionresources.com http://www.DecisionResourcesInc.com

Christopher Comfort of Decision Resources, +1-781-296-2597, ccomfort@dresources.com; or Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563, emarshall@dresources.com